Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type

Clinical relevance of comorbidity in anxiety disorders: A report from the Netherlands Study of Depression and Anxiety (NESDA)

(2012) Mieke Klein Hofmeijer-Sevink et al.   JOURNAL OF AFFECTIVE DISORDERS

S.22.01 Depression and anxiety in Parkinson's disease: under-diagnosed and undertreated

(2011) H. Wittchen et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Memory in humans is unaffected by central H1-antagonism, while objectively and subjectively measured sedation is increased

(2010) P. Van Ruitenbeek et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety

(2010) A M Perkins et al.   MOLECULAR PSYCHIATRY

Neural activity associated with monitoring the oscillating threat value of a tarantula

(2010) D. Mobbs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of Lorazepam and Citalopram on Human Defensive Reactions: Ethopharmacological Differentiation of Fear and Anxiety

(2009) A. M. Perkins et al.   JOURNAL OF NEUROSCIENCE

From Threat to Fear: The Neural Organization of Defensive Fear Systems in Humans

(2009) D. Mobbs et al.   JOURNAL OF NEUROSCIENCE

Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety

(2009) Michael Davis et al.   NEUROPSYCHOPHARMACOLOGY

Pharmacological treatment effects on eye movement control

(2008) James L. Reilly et al.   BRAIN AND COGNITION